secwatch / observer
8-K filed December 4, 2023, 6:59 PM ET CIK 0001694665
regulatory confidence high sentiment negative materiality 0.95

Evelo Biosciences, Inc.: Nasdaq/NYSE listing notice — Evelo Biosciences receives Nasdaq delisting notice; will not appeal; trading suspension Dec 12

Evelo Biosciences, Inc.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Evelo Biosciences, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5605(b)(1), 5605(c)(2), 5605(d)(2), 5605(e)(1)).

Exchange
nasdaq
Notice
delisting notice
Rules
5101, 5605(b)(1), 5605(c)(2), 5605(d)(2), 5605(e)(1)
Exact text from the filing
nd (iii) the separation of the Company’s Chief Executive Officer and Chief Financial Officer from the Company, it is the Staff’s belief that the Company no longer has an operating business and is a “public shell” as that term is defined in Nasdaq Listing Rule 5101. Terms used but defined herein are as defined under the rules of Nasdaq. The Staff also indicated that that the Company is not compliant with the following requirements for continued listing on Nasdaq: (1) $50,000,000 minimum Market Value of Listed Securities, (2) $15,000,000 minimum Market Value of Publicly Held Shares and (3) a minimum bid price of $1 per share.
View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR
accession 0001193125-23-287901
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.